Key result
Elevated CD144-EMP is linked to ~250% higher CAD risk in type 2 diabetes.
Why the study?
Clinical quantitative assessment of endothelial cell dysfunction is not established, and it is unknown whether CD144-EMP is a useful specific marker of dysfunction that predicts CAD in type 2 DM.
Observational
Answers are grounded in this paper and cite their sources.
Clinical study demonstrates CD144-positive endothelial microparticles predict coronary artery disease in type 2 diabetes, indicating their value as a quantitative vascular injury marker.
OBJECTIVES: The purpose of this study was to examine whether CD144-EMP (endothelium-derived microparticles) is useful as a specific marker of endothelial cell (EC) dysfunction and to determine whether plasma levels of circulating CD144-EMP predicted coronary artery disease (CAD) in patients with type 2 diabetes mellitus (DM). BACKGROUND: Endothelial cell dysfunction is involved in atherogenesis; however, the quantitative assessment of EC dysfunction has yet to be established clinically. Endothelium-derived microparticles are small, membrane-shed vesicles that are generated from the EC surface in response to cellular dysfunction and/or injury. Diabetes mellitus is known to be associated with EC dysfunction and accelerated atherosclerosis. METHODS: We characterized EMP using anti-CD144 (VE-Cadherin) antibody in various atherosclerosis-related cells and investigated the association between the levels of CD144-positive microparticles and hydrogen-peroxide-induced EC injury and acetylcholine-induced coronary vasomotion. Furthermore, we evaluated plasma CD144-EMP levels in patients with and without DM. RESULTS: We demonstrated that CD144-positive microparticles were derived selectively from human EC. The levels of CD144-EMP reflected the degree of in vitro hydrogen-peroxide-induced EC injury and impairment of in vivo endothelium-dependent coronary vasodilation (p < 0.01). Plasma CD144-EMP levels were increased significantly in DM patients compared with patients without DM (p < 0.001). In DM patients, the elevated levels of CD144-EMP were the most significant risk factor for CAD relative to all other traditional risk factors (odds ratio [OR] 3.5, 95% confidence interval [CI] 1.8 to 6.9, p < 0.001). Notably, plasma CD144-EMP identified a subpopulation of established CAD patients in DM subjects without typical anginal symptoms (OR 10.6, 95% CI 3.9 to 29.5, p < 0.001). CONCLUSIONS: The CD144-positive EMP exist in human plasma, and plasma CD144-EMP levels can be a clinically specific and quantitative marker of EC dysfunction and/or injury. Measurement of CD144-EMP, by providing a quantitative assessment of EC dysfunction, may be useful for identifying DM patients with increased risk of CAD.
No takes yet. Share an insight, caveat, or question.
Koga et al. (2005) conducted an observational in Type 2 diabetes mellitus and coronary artery disease. Elevated plasma CD144-EMP levels vs. Lower plasma CD144-EMP levels was evaluated on Coronary artery disease (OR 3.5, 95% CI 1.8 to 6.9, p=<0.001). In patients with type 2 diabetes, elevated levels of CD144-EMP were significantly associated with coronary artery disease (OR 3.5; 95% CI 1.8 to 6.9; p < 0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: